Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Steen, Henning; Futterer, Simon; Merten, Constanze; Jünger, Claus; Katus, Hugo A.; Giannitsis, Evangelos

doi:10.1080/10976640701544589

Cited by 39 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum concentration of cTnT in this plateau phase might be a more robust estimate for infarct size [10]. Recently, it was shown that a single value of cTnT 72–96 h after onset of acute STEMI provided an accurate estimate of infarct size determined by magnetic resonance imaging in the acute phase [11,12,13]. However, the data so far are limited, as very few patients were included in these studies.…”

Section: Introductionmentioning

confidence: 99%

Troponin T Concentration 3 Days after Acute ST-Elevation Myocardial Infarction Predicts Infarct Size and Cardiac Function at 3 Months

Bøhmer

Hoffmann²,

Abdelnoor

et al. 2009

Cardiology

View full text Add to dashboard Cite

Objectives: The evaluation of infarct size and left ventricular function after acute myocardial infarction is important for predicting the subsequent clinical course. This assessment can be achieved by non-invasive imaging methods, but biochemical assays are frequently used as an alternative. We investigated the ability of a single measurement of cardiac troponin T (cTnT) the third morning after onset of ST-segment elevation myocardial infarction (STEMI) to predict infarct size and left ventricular ejection fraction (LVEF). Methods: The study population consisted of 103 patients with their first STEMI treated with thrombolysis. Blood samples for determination of cTnT were drawn the third morning after onset of symptoms. Infarct size and LVEF were assessed by magnetic resonance imaging 3 months later. Results: Linear regression analysis showed a strong, significant correlation between third-day cTnT and infarct size at 3 months (r = 0.84, p < 0.0001). A significant but inverse and weaker correlation was obtained between third-day cTnT and LVEF (r = –0.63, p < 0.0001). Adjusting for age, gender, infarct location and medication changed the results marginally. Conclusions: A single cTnT value the third morning after onset of STEMI predicted the final infarct size in this group of patients with their first STEMI, and might be useful for ruling out impaired LVEF.

show abstract

Section: Introductionmentioning

confidence: 99%

Troponin T Concentration 3 Days after Acute ST-Elevation Myocardial Infarction Predicts Infarct Size and Cardiac Function at 3 Months

Bøhmer

Hoffmann²,

Abdelnoor

et al. 2009

Cardiology

View full text Add to dashboard Cite

show abstract

“…Cochet et al (2004) detected the MI size with MRPI and NT-proBNP plasma levels in 84 AMI patients, and found that the NT-proBNP plasma concentration was correlated with MI size (P < 0.01) and LVEF (P < 0.01). Steen et al (2007) found that NT-proBNP and troponin had important value in the evaluation of LVEF and MI size. Bruder et al (2010) reported that in 41 accurate ST stage increase patients, NT-proBNP was correlated with MI size (r = 0.74, P < 0.01), which was stronger than its relationship with LVEF (r = -0.47, P = 0.01).…”

Section: Discussionmentioning

confidence: 99%

Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction

Niu¹,

Ma²,

Xie³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. B-type natriuretic peptide (BNP) is widely used in the treatment of early-stage heart failure and coronary heart disease. In this study, the association of plasma BNP concentration with myocardial infarct (MI) size in patients with acute myocardial infarction (AMI) was investigated. Eighty patients with AMI were enrolled in the MI group and 30 healthy volunteers were selected as the control group. Magnetic resonance imaging of the heart and plasma BNP concentration detection were carried out, and then the relationship between plasma BNP concentration and MI size was analyzed in the two groups. Results showed that the plasma BNP concentration was positively related to MI size (r = 0.645, P < 0.0005), whereas it was negatively correlated to the left ventriculus ejection fraction (r = 0.297, P = 0.047). Multiple regression analysis showed that MI size was the only parameter that was independently associated with BNP (r 2 = 0.32, F = 7.712, P = 0.007). Moreover, when the BNP level reached 150 pg/mL, it had 85.1% sensitivity and 70.4% specificity of determining MI sizes exceeding 10%. The plasma concentration of BNP is highly related to MI size in patients with AMI, and can be clinically used to evaluate MI size.

show abstract

“…This makes it difficult to assign upper and lower limits to exclude or diagnose disease and, consequently, difficult to use BNP levels as a routine test, be it for diagnostic, prognostic, or monitoring purposes. Work performed to test the efficiency of combining BNP and cTn to detect and monitor IHD yielded better sensitivity and specificity (94,95), strengthening the argument for a combinatorial approach to biomarker use for clinical cardiovascular diseases.…”

Section: Fig 3 Release Profiles Of Markers Of Myocardial Injury (Admentioning

confidence: 99%

The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery

Edwards

White

Cordwell

2008

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Cardiovascular disease remains the most common cause of death in the developed world and is predicted by the World Health Organization to kill ϳ20 million people worldwide each year until at least 2015. In light of these figures, work on producing superior tools for clinical use in the cardiovascular field is intensive. As proteins are the primary effectors of cellular function, a significant majority of this work focuses on the role of proteins in the cardiovascular system in physiological and pathological states in order to outline both mechanisms and markers of disease. One of the most effective ways to investigate these on a global basis is through proteomic analysis, which allows for broad spectrum screening of cellular protein or peptide complements during cardiovascular pathogenesis. Furthermore, specific technologies are now available to screen animal model or human blood samples for novel, improved markers of chronic disease states, such as atherosclerosis or for earlier indicators of acute myocardial stress, including ischemia/reperfusion injury and heart failure. This review summarizes current literature on the key aspects of proteomics and peptidomics related to clinical cardiovascular science.

show abstract

Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Cited by 39 publications

References 33 publications

Troponin T Concentration 3 Days after Acute ST-Elevation Myocardial Infarction Predicts Infarct Size and Cardiac Function at 3 Months

Troponin T Concentration 3 Days after Acute ST-Elevation Myocardial Infarction Predicts Infarct Size and Cardiac Function at 3 Months

Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction

The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery

Contact Info

Product

Resources

About